ANANDA Scientific's Exciting New Clinical Trial
ANANDA Scientific Inc., a dedicated bio-pharmaceutical firm, and the Semel Institute for Neuroscience at the Geffen School of Medicine UCLA have announced a groundbreaking clinical trial. This study will evaluate the investigational drug Nantheia™ ATL5, which uniquely combines cannabidiol (CBD) with ANANDA's proprietary delivery technology. The primary goal is to assess the efficacy of CBD in aiding smoking cessation efforts.
Leadership of the Clinical Study
The clinical trial is spearheaded by Dr. Edythe London, who serves as a Distinguished Professor in Psychiatry and Biobehavioral Sciences, as well as in Molecular and Medicinal Pharmacology. Dr. London emphasized the significance of this research by stating, “Cigarette smoking continues to be a major health issue worldwide, and we are keen to develop new evidence-based approaches for reducing cigarette smoking and nicotine addiction.”
The Significance of Nantheia™ ATL5
Nantheia™ ATL5 is positioned as an innovative oral product, delivering 100mg of cannabidiol per softgel capsule. The trials will be conducted in a randomized, double-blind, and placebo-controlled manner, allowing researchers to draw significant conclusions about the effectiveness of this investigational drug. Participants will receive either the active drug or a placebo daily for eight weeks, aiming for a reduction in cigarette use from their baseline levels.
Endpoints and Assessment
This study’s primary endpoint will focus on the reduction of cigarette consumption. Meanwhile, secondary endpoints will delve deeper into aspects such as nicotine withdrawal effects and their impact on anxiety and mood states.
About ANANDA Scientific
ANANDA Scientific is at the forefront of biopharmaceutical research, concentrating on the development of transformative therapies for neuropsychiatric health. The company takes pride in its patented delivery technology, which enhances the bioavailability and stability of cannabinoids and other plant-derived compounds. This allows for higher efficacy and consistent absorption, setting ANANDA apart in the industry.
Planned Future Studies
ANANDA Scientific is dedicated to conducting high-caliber clinical studies not only for smoking cessation but also for various therapeutic indications. Their research spans conditions such as PTSD, opioid use disorder, anxiety, and pain management. By leveraging their patented technologies, ANANDA aims to provide patients with effective, premium pharmaceutical products that significantly improve quality of life.
Participant Involvement and Ethics
The trial intends to bring about profound changes in how smoking cessation is approached, with safety and ethical standards firmly in place for all participants. The collaboration between ANANDA and UCLA reflects a commitment to addressing significant public health challenges through scientific research and innovation.
Frequently Asked Questions
1. What is Nantheia™ ATL5?
Nantheia™ ATL5 is an investigational oral product that combines CBD with ANANDA’s proprietary delivery technology aimed at supporting smoking cessation efforts.
2. How long will the clinical trial last?
The clinical trial will run for eight weeks, during which participants will take the drug or a placebo daily.
3. Who is leading the clinical trial?
The clinical trial is led by Dr. Edythe London, a distinguished professional in the field of psychiatry and medicine.
4. What are the goals of this clinical trial?
The trial aims to reduce cigarette usage and understand the effects of CBD on nicotine withdrawal and mood states.
5. Where can I find more information about ANANDA Scientific?
More information can be found on ANANDA Scientific's official website, where updates about their research and products are regularly posted.
